Diagnostics company Meridian Bioscience (NASDAQ:VIVO) has received U.S. Food and Drug Administration clearance for a test to detect bacteria commonly associated with Legionnaires’ disease.
Legionnaires’ disease is a severe lung inflammation caused by an infection.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Cincinnati, Ohio-area Meridian said the test, called TRU Legionella, is an important addition to its respiratory product portfolio.
“This new assay solidifies our position as a leader in rapid, accurate testing methods for infectious disease testing,” CEO Jack Kraeutler said.
Meridian said the bacteria associated with Legionnaires’ disease is implicated in 5 percent to 8 percent of the 4 million to 5 million cases of community-acquired pneumonia per year in the U.S.
In December, Meridian received FDA clearances for tests for C. difficile and group B streptococcus.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
[Photo by flickr user Spec-ta-cles]
